The abbreviations used are: SA-ß-gal, senescence-associated ß-galactosidase; HPEC, human prostate epithelial cell; EST, expressed sequence tag; qRT-PCR, quantitative reverse transcriptase-PCR.
INTRODUCTION
Normal primary cells proliferate in culture for a limited number of population doublings prior to undergoing terminal growth arrest and acquiring a senescent phenotype (1) . Senescent cells are resistant to mitogen-induced proliferation, express senescence-associated ß-galactosidase (SA-ß-gal), and assume a characteristic enlarged, flattened morphology (reviewed in (2) ). With progressive cell divisions, errors in DNA replication, oxidative metabolism and environmental insults generate somatic mutations and place cells at risk for oncogenic transformation. Accumulating data suggest that the terminal arrest associated with cellular senescence represents a major barrier, analogous to apoptosis, that cells must circumvent to become malignant (3) . Research into the pathways that positively regulate senescence and ways cells bypass senescence is therefore critical in understanding carcinogenesis.
In part, senescence is mediated by loss of telomere length that occurs with progressive divisions of mortal cells (4) . Cellular senescence also can be induced prematurely by a variety of stimuli including DNA damage, perturbations of chromatin structure, and overexpression of mitogenic signals including E2F1, oncogenic H-ras, Raf or MEK (5) (6) (7) (8) . Two genes implicated in and critical for the induction and maintenance of senescence are pRb and p53 (3) .
Inactivation of the p16/pRb and p53 pathways is necessary to bypass senescence, however is insufficient for immortalization. Telomerase activation is also required, although the overexpression of telomerase alone is not sufficient to confer immortalization in epithelial cells (12) . In addition, genetic analyses of immortalized prostate epithelial and other cell types reveal a number of consistent genetic alterations are required including the amplification of chromosome 20q and 8q (13, 14) . Based on these findings, and other microcell transfer experiments, it has been proposed that alterations in multiple pathways are required for the acquisition of the immortal phenotype (15) . In a series of classical experiments the fusion of different immortalized cell lines could restore senescence and these cell lines could be sorted into four complementation groups. This work implies that there are a limited number of pathways critical to senescence, that these pathways must be activated to initiate senescence, and that they can override other transforming genetic events to yield a senescent phenotype (16) .
Genes that have been implicated in senescence are also targeted in the development and progression of human prostate and bladder cancer. The p16/pRb pathway is altered in 85% of primary prostate cancers and predicts adverse clinical outcome (17) . The tumor suppressor p53 is one of the most commonly mutated genes in human cancer and is altered frequently in advanced prostate and bladder cancers (18, 19) . Several lines of evidence suggest that bypassing senescence may also be important in cancer progression in vivo. Immortalized colon cancer cell lines can only be established from large, pathologically advanced lesions (20) . When noninvasive papillary bladder neoplasms are grown in culture, they uniformly senesce and maintain an intact p16/pRb pathway (19, 21) . In contrast, cells cultured from myoinvasive, aggressive transitional cell bladder carcinomas do not senesce, have alterations of the p53 pathway and inactivate either p16 or pRb. Furthermore, prostate tumors that grow as xenografts have been generated solely from advanced, metastatic cancers (22). These results suggest that bypassing senescence is important in cancer progression, and occurs late in the progression of cancers in vivo.
To gain insight into novel pathways involved in bypassing senescence, we developed a model in which transcript levels for over 20,000 unique sequences were tracked in replicate cultures as human prostate epithelial cells senesced or were immortalized. A major advantage of this approach is that it avoids exogenous gene expression for the induction of premature senescence that can result in biased or aberrant results. Using this strategy, we have identified several genes, BRAK, DOC1, and IGFBP-3, which are upregulated in senescence and inactivated during immortalization.
We find utilizing quantitative RT-PCR, that these genes are significantly downregulated in human prostate cancer cell lines and xenografts. Interestingly, all of these genes have been previously implicated in the tumorigenic phenotype (23-25). These data support the concept that pathways activated at senescence and selectively inactivated with immortalization are important in carcinogenesis and tumor progression. Furthermore, these results provide an important effort in cataloging genes altered in senescence, a biologically relevant model of aging.
MATERIALS AND METHODS
Cell Culture-Prostate tissue was obtained under an approved IRB protocol from men (ages 44-66) undergoing cystoprostatectomy for bladder cancer at the University of Wisconsin Hospitals and Clinics. Histology confirmed that no bladder or prostate cancer was present in the tissues harvested for our studies. Prostate epithelial cultures were established as described previously (13).
Prostate tissues were minced with a scalpel and digested in a solution containing 500 U/ml collagenase (Sigma) and plated on collagen-coated plates. Cells were maintained in Ham's F-12 media (Life Technologies, Inc.) supplemented with regular insulin, 0.25 units/ml; hydrocortisone, 1 µg/ml; human transferrin, 5 µg/ml; dextrose, 2.7 mg/ml; non-essential amino acids, 0.1 mM; penicillin, 100 units/ml; streptomycin,100 µg/ml; L-glutamine, 2 mM; cholera toxin, 10 ng/ml; bovine pituitary extract, 25 µg/ml and 1% FBS (26) . Cells were passaged when confluent after incubation with trypsin-EDTA. Proliferating cells were harvested 2 days following the first passage.
Pre-senescent cells were harvested when cell growth ceased, 1-5% of all cells appeared morphologically circular, flattened and enlarged, and SA-ß-gal expression was negative.
Terminally-senescent cells were harvested when >60% appeared morphologically senescent and expressed high levels of SA-ß-gal.
Transformation of HPECs with HPV16 E6 and/or E7-Infections and characterization of
HPEC cell lines was carried out as described (13). We used a retrovirus construct carrying either the HPV16 E6 and/or E7 gene(s) as well as a gentamicin resistance cassette (received from Dr. D.
Galloway, Seattle, WA) (27) . Sub-confluent proliferating HPECs were infected with 10 3 -10 5 infectious viral units at pre-passage (~5 X 10 5 cells per 100-mm dish) in 3 ml of 1% FBS, F-12+ containing 4 µg/ml polybrene (Sigma). After 6 hours, the virus containing media was exchanges and infected cells were selected with 50 µg/ml of G418 (Life Technologies, Inc.) for a minimum of 7 days. Immortalized cell lines were screened for HPV16 E6 and/or E7 protein expression and loss of p53 and pRB by western blot analysis. All immortalized lines were passaged in 1% FBS F-12+ for well over 20 times to confirm their immortality.
Microarray Hybridizations and Data Analysis-Microarray manufacture and
hybridizations were carried out in accord with previously published methods available at (28) .
For this set of experiments we used DNA microarrays with either 41,000 or 47,000 spots representing over 20,000 unique human genes and expressed sequence tags (ESTs). For each hybridization, two micrograms of poly(A) mRNA from each sample were reverse-transcribed and labeled with fluorescence-tagged nucleotides (Cy3 for the reference sample, Cy5 for the experimental sample). Samples were hybridized against a common reference pool of mRNA derived from a panel of human cell lines, as described previously (29) . Hybridizations were carried out for 16-18 hours at 65°C and the arrays were washed. After drying, the microarrays were scanned with a confocal laser GenePix microarray scanner (Axon Instruments) and were procedure computes a two-sample T-statistic (e.g. proliferating vs. senescent HPECs) for the normalized log ratios of gene expression levels for each gene. It thresholds the T-statistics to provide a "significant" gene list and provides and estimate of the false discovery rate (the percent of genes identified by chance alone) from randomly permuted data.
For the experiments described in our study, the raw expression ratio dataset was filtered, using the program Cluster, for genes whose transcript levels differ from their median value by at least 1.5-fold in androgen treated cells compared to controls in at least 2 experiments (with not more than 30% of measurements discarded due to poor data quality for each entry). We selected a dataset in which 0.5 is the median number of likely false positive genes (false detection rate of 0.088%) for further analysis. We selected this value because it provided statistical assurance that most genes in the set were significantly altered, but was not so stringent as to exclude genes of biological interest.
Quantitative RT-PCR analysis-Total RNA was isolated using the RNeasy RNA isolation kit (Qiagen), DNAse treated and 1 µg was used to prepare cDNA. Quantitative RT-PCR was performed by monitoring in real time the increase in fluorescence of the SYBR Green dye as described using a iCycler detection system (Bio-Rad) (32, 33) . For comparison of transcript levels between samples, a standard curve of cycle thresholds for several serial dilutions of a cDNA sample was established. This value was then used to calculate the relative abundance of each gene. These values were then normalized to the relative amounts of 18S cDNA. All PCR reactions were performed in duplicate. Sequences of primers used for PCR analysis are available upon request. that p16 and p53 function as tumor suppressors, in part, by inducing senescence pathways (37) . We have previously reported at the cdk inhibitor p16 protein level, a known marker of senescent cells, is elevated at senescence (34) . In this study, we find ~50-fold increase in p16 mRNA at senescence, suggesting that p16 protein increases are due, at least in part, to increased transcription. Transcript levels of other negative growth regulators were also increased including the p53-regulated targets BTG2, p21, IGFBP-3 and mdm2 (Fig. 1A) , suggesting elevated p53 activity at senescence.
RESULTS AND DISCUSSION

Analysis of Senescence Pathways in Human Prostate
Overexpression of BTG2 (38) , p21 (39), IGFBP-3 (25) and even mdm2 in normal diploid cells (40) can result in G0/1 cell cycle arrest. These p53-inducible genes may reflect the participation of p53 in regulating the onset of senescence and lend further insight into senescence-associated p53 targets.
Senescent cells show permanent growth arrest and express markers associated with terminal differentiation. Consistent with this phenotype, 15 of 51 genes induced in senescent cells are associated with differentiation, 10 of which are commonly expressed in neuronal tissue (Fig. 1A) .
These genes may be indicative of the terminally differentiated phenotype rather than the induction of array, respectively). Senescent cells produce extracellular proteases that promote matrix and basement membrane degradation, and these changes are thought to contribute to the aging process in vivo (42) . Our data suggest that senescence is associated with significant alterations of the ECM, and provides some of the molecular underpinnings for these matrix changes.
The finding that the ras homolog gene family member B (RhoB) was induced at senescence is novel. RhoB mRNA levels were induced 3.6-fold by cDNA array and confirmed with real-time quantitative PCR (17-fold increase, Fig. 2A ). It has been demonstrated that the overexpression of oncogenic H-ras promotes senescence in primary, mortal epithelial cells and fibroblasts (6); however we did not observe changes in H-ras expression during senescence in our HPEC expression
profiles. RhoB appears to have several functions in the cell including negative growth regulation, the induction of cytoskeletal changes, and sensitizing cells to apoptosis (43, 44) . In aging mice, RhoB expression was found to be induced in skeletal muscle and this alteration was attenuated with caloric restriction, the only known mechanism for retarding the aging process (45) . Collectively, these data suggest that RhoB may be integral to both senescence and the aging process, potentially contributing to both the growth arrest and the characteristic morphology observed in senescent cells. other validation experiments performed using this array system (46) . However, microarrays tended to underestimate changes in transcript levels when genes were induced or repressed over ~3 fold.
Many of the gene expression changes we observed are also observed in primary fibroblasts undergoing senescence (Table 1) . However, in contrast to senescent fibroblasts, HPECs show increased transcript levels of the retinoic acid receptor α, interleukin 1α, interleukin 6, and IGF-I at terminal-senescence. These differences in expression may be cell-type specific or may reflect differences between epithelial cells and fibroblasts (29) . Comparison of limited expression profiles from fibroblasts to our data derived from HPECs are extraordinarily consistent suggesting that pathways that regulate senescence are conserved among cells derived from different tissues. (Fig. 1B) . In addition, genes involved in DNA damage response were also upregulated during immortalization (Fig. 1B) . It is unclear whether induction of these repair genes reflects increased DNA surveillance, or an enhanced DNA repair capacity.
Identification of pathways and genes altered following HPEC immortalization-To
Identification of genes associated with bypassing senescence in prostate cancer
cells-We hypothesized that a gene whose expression is induced during senescence (activation) and repressed following immortalization (inactivation) could be targeted during prostate cancer progression. Hierarchical clustering analysis was performed on genes whose expression changed greater than 1.5-fold as cells progressed to senescence or following immortalization to identify a group of genes with elevated transcript levels at senescence that returned to levels below or comparable to normal proliferating cells upon immortalization (Fig. 3) . To further identify genes that may be inactivated during carcinogenesis, we focused on transcripts induced in senescent To extend these findings, we analyzed the expression of BRAK, DOC1, and IGFBP-3 levels in the human prostate cancer cell lines LNCaP, Du145, TSU, PPC-1, PC-3 and DuPro using qRT-PCR. In 6/6 tumorigenic, immortalized prostate cancer cell lines we found DOC-1 to be downregulated roughly 23 fold, and BRAK and IGFBP-3 expression to be undetectable (Fig. 4) . We analyzed the expression levels of these three genes in two additional human prostate cancer xenografts LAPC4 and LAPC9 to evaluate whether their expression is also lost in vivo. Similar to the prostate cancer cells, expression of BRAK, DOC1 and IGFBP-3 were all reduced markedly in these models compared to normal HPECs (Fig. 4) . These prostate cancer xenografts have not been expression is associated with prostate cancer progression, demonstrating more frequent loss of expression in advanced disease, in both human and mouse models (25,51,52). Our data suggest that this may be due to bypassing senescence pathways. Another factor implicating IGFBP-3 in a senescence pathway is that the HPV16 E7 oncoprotein targets IGFBP-3 for inactivation (53).
Further study of prostate cancer specimens will be necessary to evaluate the role of BRAK and DOC1 specifically in prostate cancer. These findings underscore the potential importance of inactivation of senescence in carcinogenesis and tumor progression.
In summary, using DNA microarray analysis, we have identified genes participating in normal human prostate epithelial cell senescence. We suspect these pathways participate in the induction of senescence in many other cell types and these genes are members of a limited number of pathways that can be inactivated to bypass senescence during tumorigenesis (15) . We also have identified novel markers for the senescent phenotype that could assist in an analysis of the role of senescence in normal and pathologic states in vivo (54). Future studies will explore whether reactivation of these pathways in immortalized cells can also re-establish cellular senescence and whether this may represent a novel therapeutic approach to prostate cancer. immortalized HPECs. Relative expression levels were normalized to the 18S content, also determined by RT-PCR, and plotted on a log scale as fold change compared to proliferating cells.
Expression levels from three separate microarray experiments were averaged and plotted with the qRT-PCR data for comparison. Good correlation was observed for all transcript levels, although the DNA microarrays tended to under estimate changes in transcript levels at higher magnitudes. 
